# Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety

> **NCT01142284** · PHASE2 · COMPLETED · sponsor: **Korea Otsuka Pharmaceutical Co., Ltd.** · enrollment: 80 (actual)

## Conditions studied

- Peripheral Artery Disease

## Interventions

- **DRUG:** Cilostazol, Probucol

## Key facts

- **NCT ID:** NCT01142284
- **Lead sponsor:** Korea Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-05-19
- **Primary completion:** 2012-11-29
- **Final completion:** 2012-12-18
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2022-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142284, "Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and Safety". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01142284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*